Goldman Sachs
PLX icon

Goldman Sachs’s Protalix BioTherapeutics PLX Stock Holding History

Goldman Sachs’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,250
Closed -$82K – 7227
2014
Q2 		$82K Buy
+2,250
New +$90.8K ﹤0.01% 6634

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs's PLX Position: Q2 2026 in Review

Goldman Sachs increased its Protalix BioTherapeutics (PLX) stake by 89% in Q2 2026, buying an estimated $476K and bringing the position to 475,922 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #5131.

Goldman Sachs first reported a position in PLX in Q2 2013 and has held it in 29 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Goldman Sachs held 475,922 shares of Protalix BioTherapeutics worth $1.11M as of Q2 2026.
  • Goldman Sachs bought 224,577 Protalix BioTherapeutics shares in Q2 2026, an estimated $476K.
  • Protalix BioTherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5131 holding.
  • Goldman Sachs first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 29 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.